Skip to main content
. 2015 Jan 6;23(2):270–277. doi: 10.1038/mt.2014.209

Figure 2.

Figure 2

A single scAAV9-siPTEN injection improves weight gain and extends the lifespan of the SMNΔ7 mouse model of SMA. (a) Images showing the same SMNΔ7 pups at different ages as indicated; for reference, a gender-matched carrier littermate was included. The pups were injected at postnatal day 1 with either scAAV9-siPTEN or scAAV9-scrambled-siPTEN. (b) Body weight increase in SMNΔ7 mice injected with scAAV9-siPTEN or scAAV9-scrambled-siPTEN from postnatal days 2–20. Body weight of scAAV-siPTEN injected mice was significantly greater than that of scAAV9-scrambled-siPTEN mice from day 11 onward (P < 0.05 two-way ANOVA with Bonferroni post hoc test). Untreated and carrier groups were included as controls. (c) Percentage of mice able to complete the righting reflex test. Mice were placed on their backs and were deemed successful if they were able to reorientate within 30 seconds. scAAV9-siPTEN–injected mice improved gradually over the first 15 days, by which time all mice were able to complete the test. (d) Kaplan–Meier cumulative survival curves in the different experimental groups. scAAV9-siPTEN–treated mice lived significantly longer than scAAV9-scrambled-siPTEN or SMNΔ7 controls (P < 0.01).